Kyowa Kirin Co., Ltd.

Established Kirin Beer Co., Ltd.

Founded Kohwa Fermentation Industry Co., Ltd.

Introduced streptomycin manufacturing technology from Merck & Co., USA, and became the first in Japan to mass-produce streptomycin. Contributed to the eradication of tuberculosis.

Introduced streptomycin manufacturing technology from Merck & Co., USA, and became the first in the country to mass-produce streptomycin. Contributed to tuberculosis eradication. (Initiated pharmaceutical business activities)

Isolated the anticancer agent mitomycin C and succeeded in industrialization. Invented the first fermentation-based production technology for L-glutamic acid worldwide, pioneering the amino acid fermentation business.

Isolated the anticancer agent Mitomycin C and successfully industrialized it. Invented the first fermentation-based production technology for L-glutamic acid worldwide, pioneering the amino acid fermentation industry.

Launched the anticancer agent 'Mitomycin' and the antibiotic 'Spiramycin'.

Launched the anticancer agent "Mitomycin" and the antibiotic "Spiramycin".

Launched the anticancer agent '5-FU' and the antibiotic formulation 'Acetylspiramycin'.

Launched the anticancer agent "5-FU" and the antibiotic formulation "Acetylspiramycin".

Launched the anticancer agent 'Loinase®'.

Launch of the anticancer drug 'Roineze®'.

Commenced serious research aimed at pharmaceutical development of erythropoietin.

Supported the establishment of the Lahoja Allergy Immunology Institute in the United States.

Supported the establishment of the LaHoya Allergy Immunology Institute in the United States.

Launched the renal anemia treatment drug 'Espo®' (EPO formulation).

Launch of the renal anemia treatment drug 'Espo®' (EPO formulation).

Launched the neutropenia treatment drug 'Gran®' and the hypertension/angina treatment drug 'Conir®'.

Launch of the neutropenia treatment drug 'Gran®' (G-CSF agent). Launch of the hypertension and angina treatment drug 'Conir®'.

Established technology for producing fully human antibodies.

Established technology for producing fully human antibodies.

Launched the allergy treatment drug 'Alerock®' tablets.

Launch of the allergy treatment drug 'Alerock®' tablets.

Established the antibody drug business company 'BioWa, Inc.' in the United States.

Launched the antihistamine eye drop 'Patanol® Eye Drops'.

Launch of the anti-allergy eye drop 'Patanol®' eye drops.

With the introduction of a pure holding company structure for Kirin Beer, 'Kirin Pharma Co., Ltd.' was established. Launched the sustained-release erythropoietin-stimulating agent 'Nesup®'.

With the introduction of a pure holding company structure for Kirin Brewery Co., Ltd., Kirin Pharma Co., Ltd. was established. Launch of the long-acting erythropoiesis-stimulating agent 'Nesup®'. Established new technology 'COMPLEGENT®' to enhance antibody drug activity.

Launched the secondary hyperparathyroidism treatment drug 'Regpara®'. Split off the biochemicals business and established Kyowa Fermentation Bio Co., Ltd. Established Kyowa Fermentation Kirin Co., Ltd.

Launch of the secondary hyperparathyroidism treatment drug 'Regpara®' tablets. The biochemicals business was spun off, establishing Kyowa Hakko Bio Co., Ltd. Kyowa Hakko Kirin Co., Ltd. was established.

Established 'Our Vision'.

Launch of the platelet hematopoietic growth factor product "Lomiplate®". Acquired UK-based ProStrakan as a subsidiary.

Launch of the platelet-stimulating factor agent/thrombopoietin receptor agonist 'Lomiplate® subcutaneous 250µg for preparation'. Acquired ProStrakan Ltd. of the United Kingdom as a subsidiary.

Established the joint venture "Kohwa Kirin Fuji Film Biologics" with Fujifilm. Launched the adult T-cell leukemia/lymphoma therapy "Poterijio®".

Established the joint venture 'Kyowa Kirin Fujifilm Biologics Co., Ltd.' with Fujifilm for development, manufacturing, and sales of biosimilar medicines. Launch of the adult T-cell leukemia/lymphoma (ATL) treatment drug 'Potelijio® IV infusion 20mg'.

Launched the new Parkinson's disease therapy "Nourialist®". Launched the sustained-release G-CSF product "Zirasta®".

Launch of the new Parkinson's disease treatment drug 'Nourialist® tablets 20mg'.

UK-based ProStrakan acquired Archimedes. Launched the sustained-release G-CSF product "Zirasta®".

ProStrakan Ltd. of the United Kingdom acquired Archimedes. Launch of the long-acting G-CSF agent 'Zirasta® subcutaneous 3.6mg'.

Unified the Kyowa Kirin brand. Commenced domestic sales of the psoriasis therapy "Lumisef®".

Unified Kyowa Kirin brand. Commenced domestic sales of the psoriasis treatment drug 'Lumisef®'.

Established Kohwa Kirin Frontier Co., Ltd.

Obtained approval in the US and Europe for the X-linked hypophosphatemia therapy "Crysvita" and the cutaneous papilloma/Sezary syndrome therapy "Poteligeo".

Obtained approval in Europe and the United States for the X-linked hypophosphatemia treatment drug Crysvita® and the treatment drugs for cutaneous papilloma and Cezary syndrome, Poteligeo®.

Renamed to Kohwa Kirin Co., Ltd. Launched the hypophosphatemia therapy "Crysvita®" and Parkinson's disease therapy "Nourianz™" in Japan and the United States.

Renamed to Kyowa Kirin Co., Ltd. Launched the FGF23-related hypophosphatemic osteomalacia treatment drug 'Crysvita®' in Japan. Launched the Parkinson's disease treatment drug 'Nourianz™' in the United States.

Launched the cutaneous papilloma/Sezary syndrome therapy "Poteligeo®" in Europe. Obtained additional indication approval for "Crysvita®" in the US for tumor-induced osteomalacia.

Released Poteligeo® for cutaneous papilloma and Cezary syndrome in Europe. Obtained additional indication approval for Crysvita® for tumor-induced osteomalacia (TIO) in the United States.

Formulated a new vision for 2030. Entered a joint development and commercialization agreement with Amgen for the anti-OX40 monoclonal antibody KHK4083.

Formulated a new vision for 2030, aiming for life-changing value. Entered a joint development and sales agreement with Amgen for the company's own human anti-OX40 monoclonal antibody KHK4083. Expressed support for the Task Force on Climate-related Financial Disclosures (TCFD) recommendations.

Established a global DE&I declaration with a target of 40% female leaders. Launched the automated infusion device for "Zirasta®" in Japan. Completed the Q-TOWER analytical facility at the Takasaki plant.

Established a global DE&I declaration, aiming to achieve 40% female leadership globally by 2030. Launched the automatic injection device 'Zirasta® subcutaneous 3.6mg BodyPod' for the long-acting G-CSF agent Zirasta® in Japan. Completed the Q-TOWER biopharmaceutical analysis facility at the Takasaki plant.

Please be aware of emails that impersonate Kyowa Kirin's company name and our executives.

Obtained domestic approval for the hyperphosphatemia therapy "Fozebel®". Announced acquisition of UK-based Orchard Therapeutics.

Obtained domestic approval for the hyperphosphatemia treatment drug Fozebel®. Announced acquisition of UK-based Orchard Therapeutics plc, which has hematopoietic stem cell gene therapy technology.

Secured FDA approval and launched the hematopoietic stem cell gene therapy "Lenmeldy®". Decided to build a new biopharmaceutical plant in the United States. Entered a global development and sales agreement for "ziftomenib".

Hematopoietic stem cell gene therapy Lenmeldy™ (atidarsagene autotemcel) received FDA approval and launch in the United States. Decided to build a new biopharmaceutical plant in North Carolina, USA. Entered into a strategic partnership with Kura Oncology for global development and sales of the menin inhibitor ziftomenib targeting acute leukemia.

Established the HB7 building for biopharmaceutical active ingredient manufacturing at the Takasaki plant. Secured FDA approval and began sales of the adult acute myeloid leukemia therapy "KOMZIFTI®".

Established Building HB7 at the Takasaki plant to manufacture biopharmaceutical APIs, strengthening global production capacity and biomanufacturing talent development. Adult acute myeloid leukemia drug KOMZIFTI™ (ziftomenib) received FDA approval and began sales in the United States.